Why the recovery timeline follows biology, not pain levels

Full recovery from a Liquid Cartilage™ (ChondroFiller™) hip injection takes up to two years — not because the procedure is complex, but because human biology cannot be hurried. Understanding that distinction makes the difference between a successful outcome and an avoidable setback.

The treatment itself is straightforward: ChondroFiller™ is an acellular Type I collagen scaffold delivered as an outpatient, ultrasound-guided injection directly into the hip joint. There is no incision, no theatre admission, and no general anaesthetic. Once placed, the collagen solution self-gels within 3–5 minutes and bonds immediately with the synovial fibrin lining the defect, creating a stable three-dimensional framework.

What happens next is entirely down to the patient's own biology. Over the following days and weeks, the body's progenitor cells — drawn from the surrounding synovium and subchondral bone — migrate into that framework and gradually mature into cartilage-forming chondrocytes. The scaffold supports this process by providing the right chemical and structural environment; it does not supply cells itself. Over 12 to 24 months, the collagen matrix is progressively resorbed and replaced by the patient's own hyaline-like cartilage tissue.

This biology-paced timeline has one critical implication: feeling comfortable early in recovery does not mean the scaffold is ready for load. Phase transitions are determined by clinical review and the underlying repair timeline, not by the absence of pain.

The first 48 hours after your hip injection

Most patients leave the Grantham or Sleaford clinic within the hour — there is no overnight stay and no theatre recovery.

For the first 24–48 hours, rest the hip and avoid sustained walking or prolonged standing. Some localised swelling around the joint, a temporary flare in hip pain, and morning stiffness are all normal; they typically settle within a few days as the collagen gel stabilises. Paracetamol is the recommended first-line pain relief; ibuprofen may be added where it is not contraindicated.

Crutches are issued for the early Protect phase and should be used as instructed by Prof Paul Lee's team — they are not optional. Keeping load through the hip within the prescribed limits during this window directly protects the newly formed scaffold while progenitor cells begin migrating in.

Contact the clinic if you notice: significant or worsening joint swelling beyond the first 48 hours, a fever, redness that is spreading, or pain that is severe and not settling with analgesia. These are uncommon but warrant a prompt call to the Lincolnshire Hip team.

Weeks one to six: keeping the scaffold stable

Six weeks is the single most important window in the entire recovery. The collagen scaffold has gelled, but progenitor cell migration into that framework takes days to weeks to establish — meaning the scaffold is structural but not yet reinforced by the patient's own tissue. Any loading pattern that shears or displaces the gel before cellular colonisation is underway risks compromising the repair from the outset. Each restriction below has that biology at its root.

• Crutch-assisted walking only, with touch-down weight of around 5–20 kg through the hip. Light axial load at low magnitude is tolerated; uncontrolled weight shifts and uneven surface forces are not.
• No deep hip flexion beyond roughly 90 degrees. Low car seats, soft sofas, and deep chairs all push the hip into this range — a firm cushion raises effective seat height and is worth using consistently.
• No twisting, pivoting, or lateral rotation. Rotational forces are especially destabilising to a freshly gelled scaffold; turn by moving the feet rather than the torso.
• No prolonged standing, and no more than one flight of stairs in a single outing. Sustained load fatigues hip musculature, reducing its shock-absorbing role at precisely the time the scaffold depends on it most.

Gentle range-of-motion exercises prescribed by the physiotherapist — typically hip circles and careful flexion-extension within comfortable limits — may begin within this window. Their purpose is preventing stiffness and maintaining joint nutrition, not building strength.

Patients treated via the outpatient injection route typically follow a modestly lighter early loading protocol than guidelines written for arthroscopic theatre-based placement. The six-week stabilisation principle applies equally to both delivery routes: the scaffold needs undisturbed time to support cell migration before load is progressively reintroduced.

Weeks six to twelve: rebuilding hip strength

Discarding the crutches at around week six marks a genuine turning point — though what follows is active work rather than a gradual return to normal life on its own terms. At the six-week clinical review, the treating team confirms that the scaffold has had sufficient time to stabilise, and structured physiotherapy begins in earnest.

The focus in this phase is hip muscle strength and joint stability. Hip abductor and external rotator strengthening, pelvic control, and gait re-education form the core of a supervised physiotherapy programme. This is active, progressive rehabilitation — not passive treatment — because the muscles surrounding the hip joint are the scaffold's principal mechanical protection once crutches are gone. Strong, well-coordinated hip musculature reduces peak cartilage contact forces, which matters as the new tissue matures over the months ahead.

Normal walking on flat surfaces is reintroduced progressively, building from shorter distances toward a more natural stride pattern. Stationary cycling and pool-based exercise — aqua walking, gentle swimming — are typically permitted during weeks six to twelve. These are not simply tolerated; low-impact cyclical loading actively supports cartilage nutrition by driving synovial fluid into the joint without subjecting the maturing scaffold to the spike forces that running or twisting would create.

Running, jumping, pivoting, and any activity requiring rapid directional change remain off-limits throughout this phase. This phase is best understood as laying the groundwork — the muscle and stability base that makes functional loading possible in the months that follow.

Months two to twelve: returning to full hip function

From month two onward, the recovery arc shifts from protection to progressive challenge — and the pace becomes increasingly individual.

Between months two and four, jogging and hip-specific movement drills are introduced under physiotherapist supervision, typically on flat ground and at low intensity to begin with. Gym-based lower-limb strengthening generally follows around months three to four: hip press, controlled step work, resistance band exercises targeting the abductors and rotators. Think of this as the phase where walking the dog becomes genuinely comfortable, and cycling to work starts feeling realistic rather than aspirational.

Months four to six bring a progressive return to recreational activity as tolerated and reviewed at clinical check-ins. Recreational golf, gentle hiking on the Lincolnshire Wolds, and light manual tasks are reasonable targets during this window — provided hip loading is graduated and any soreness settles within 24 hours of activity. Heavier dynamic work, prolonged manual labour, and sustained running remain supervised rather than self-directed.

From month six onward, running, high-impact training, and loading sports are graduated toward the 12-month mark as scaffold matrix maturation advances. Twelve months is the earliest realistic point for full return to high-impact activity — not an automatic green light, but the threshold at which the scaffold is sufficiently replaced by the patient's own tissue to support it.

Return to competitive sport or physically demanding employment is typically assessed at or after 12 months. Body weight, hip anatomy, defect size, and age all influence how quickly any individual moves through these sub-phases — progression is guided by clinical review, not a fixed calendar.

What Lincolnshire patients can realistically expect at one to five years

Published evidence from ChondroFiller-treated cohorts reports 70–85% of patients achieving meaningful symptom relief at three to five years — a figure drawn from hip, knee, and other joint cohorts. The hip-specific outcome anchor is a modified Harris Hip Score improvement of approximately 30 points: in daily life terms, that is the difference between struggling to dress independently or walk a quarter of a mile and returning to gardening, recreational walking, or work on your feet with real confidence. A 2025 ex vivo osteochondral model added direct biological grounding to these numbers — DNA content within scaffold-treated defects was 2.4 times higher by day 14 than in untreated controls, confirming that the collagen matrix actively recruits the patient's own cells rather than passively filling space.

The evidence gap deserves a plain statement: long-term data specifically for the outpatient injection route in the hip is still emerging. Most published cohorts used arthroscopic delivery or included mixed joints, and a hip-only injection RCT with five-year follow-up has not yet been published. The available evidence is substantive, but its scope is not identical to the injectable pathway offered in Lincolnshire.

What tends to separate patients who reach the 12-month milestone in good shape is adherence to the biology-paced structure of recovery — protecting the scaffold during the first six weeks, committing to the physiotherapy that follows, and resisting the pull toward impact activity before the scaffold-to-tissue transition is sufficiently advanced. The numbers are encouraging; the recovery work is what makes them accessible.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment in Grantham or Sleaford under Professor Paul Lee.

1. [1] Rates of Achieving Meaningful Outcomes 5-Years After Microfracture Augmented with Allograft Cartilage for Hip Chondral Defects. (2025). https://doi.org/10.1177/2325967125s00203 https://doi.org/10.1177/2325967125s00203